{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:03:33Z","timestamp":1789736613436,"version":"4.0.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41571-026-01186-3","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T09:42:10Z","timestamp":1785318130000},"page":"792-805","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["De-escalation trials in multiple myeloma: past, present and future"],"prefix":"10.1038","volume":"23","author":[{"given":"Hira","family":"Mian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-2469","authenticated-orcid":false,"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Garfall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"1186_CR1","doi-asserted-by":"publisher","first-page":"6915","DOI":"10.1182\/blood-2024-201794","volume":"144","author":"E Ortega","year":"2024","unstructured":"Ortega, E., Fe Bitaube, R., Verdugo Cabeza De Vaca, V., Gavira, R. & Garz\u00f3n, S. How much has the overall survival of multiple myeloma patients improved after the incorporation of new drugs in the first line of treatment in Real-World Experience (RWE)? [abstract]. Blood 144, 6915\u20136916 (2024).","journal-title":"Blood"},{"key":"1186_CR2","unstructured":"Gay, F. et al. Modeling long-term progression-free survival in transplant-eligible and transplant-ineligible newly diagnosed multiple myeloma treated with daratumumab, bortezomib, lenalidomide, and dexamethasone. Preprint at ResearchGate https:\/\/bit.ly\/4gUie4e (2025)."},{"key":"1186_CR3","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","volume":"208","author":"R Alexanian","year":"1969","unstructured":"Alexanian, R. et al. Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA 208, 1680\u20131685 (1969).","journal-title":"JAMA"},{"key":"1186_CR4","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMra041875","volume":"351","author":"RA Kyle","year":"2004","unstructured":"Kyle, R. A. & Rajkumar, S. V. Multiple myeloma. N. Engl. J. Med. 351, 1860\u20131873 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1186_CR5","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M Attal","year":"2003","unstructured":"Attal, M. et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 349, 2495\u20132502 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1186_CR6","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1200\/JCO.21.01045","volume":"39","author":"P Sonneveld","year":"2021","unstructured":"Sonneveld, P. et al. Consolidation and maintenance in newly diagnosed multiple myeloma. J. Clin. Oncol. 39, 3613\u20133622 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1186_CR7","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk, N. W. C. J., Pawlyn, C. & Yong, K. L. Multiple myeloma. Lancet 397, 410\u2013427 (2021).","journal-title":"Lancet"},{"key":"1186_CR8","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar, S. K. et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28, 1122\u20131128 (2014).","journal-title":"Leukemia"},{"key":"1186_CR9","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy, P. L. et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366, 1770\u20131781 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1186_CR10","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal, M. et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366, 1782\u20131791 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1186_CR11","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","volume":"4","author":"SA Holstein","year":"2017","unstructured":"Holstein, S. A. et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 4, e431\u2013e442 (2017).","journal-title":"Lancet Haematol."},{"key":"1186_CR12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.406.406","volume":"122","author":"M Attal","year":"2013","unstructured":"Attal, M. et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma: follow-up analysis of the IFM 2005-02 trial [abstract]. Blood 122, 406 (2013).","journal-title":"Blood"},{"key":"1186_CR13","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi, N. C. et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 4, 5988\u20135999 (2020).","journal-title":"Blood Adv."},{"key":"1186_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld, P. et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 390, 301\u2013313 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1186_CR15","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","volume":"31","author":"SZ Usmani","year":"2025","unstructured":"Usmani, S. Z. et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat. Med. 31, 1195\u20131202 (2025).","journal-title":"Nat. Med."},{"key":"1186_CR16","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1056\/NEJMoa2514663","volume":"394","author":"J Costa Luciano","year":"2026","unstructured":"Costa Luciano, J. et al. Teclistamab plus daratumumab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 394, 739\u2013752 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1186_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01139-y","volume":"14","author":"AJ Devasia","year":"2024","unstructured":"Devasia, A. J., Chari, A. & Lancman, G. Bispecific antibodies in the treatment of multiple myeloma. Blood Cancer J. 14, 158 (2024).","journal-title":"Blood Cancer J."},{"key":"1186_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar, S. V. et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11, 29\u201337 (2010).","journal-title":"Lancet Oncol."},{"key":"1186_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie, B. G. M. et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389, 519\u2013527 (2017).","journal-title":"Lancet"},{"key":"1186_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"BGM Durie","year":"2020","unstructured":"Durie, B. G. M. et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 10, 53 (2020).","journal-title":"Blood Cancer J."},{"key":"1186_CR21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bjh.15261","volume":"182","author":"EK O\u2019Donnell","year":"2018","unstructured":"O\u2019Donnell, E. K. et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br. J. Haematol. 182, 222\u2013230 (2018).","journal-title":"Br. J. Haematol."},{"key":"1186_CR22","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","volume":"116","author":"S Bringhen","year":"2010","unstructured":"Bringhen, S. et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 116, 4745\u20134753 (2010).","journal-title":"Blood"},{"key":"1186_CR23","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3324\/haematol.2013.099341","volume":"99","author":"M Mar\u00eda-Victoria","year":"2014","unstructured":"Mar\u00eda-Victoria, M. et al. Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica 99, 1114\u20131122 (2014).","journal-title":"Haematologica"},{"key":"1186_CR24","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo, A. et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J. Clin. Oncol. 32, 634\u2013640 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1186_CR25","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"M-V Mateos","year":"2010","unstructured":"Mateos, M.-V. et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 11, 934\u2013941 (2010).","journal-title":"Lancet Oncol."},{"key":"1186_CR26","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood-2024-209653","volume":"144","author":"G Cook","year":"2024","unstructured":"Cook, G. et al. IMWG frailty score-adjusted therapy delivery reduces the early mortality risk in newly diagnosed tne multiple myeloma: results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial [abstract]. Blood 144, 673\u2013674 (2024).","journal-title":"Blood"},{"key":"1186_CR27","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1002\/cncr.34987","volume":"129","author":"AK Nooka","year":"2023","unstructured":"Nooka, A. K. et al. Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: final analysis of the DREAMM-2 trial. Cancer 129, 3746\u20133760 (2023).","journal-title":"Cancer"},{"key":"1186_CR28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41591-023-02703-y","volume":"30","author":"S Trudel","year":"2024","unstructured":"Trudel, S. et al. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1\/2 trial. Nat. Med. 30, 543\u2013551 (2024).","journal-title":"Nat. Med."},{"key":"1186_CR29","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1182\/blood.2020009507","volume":"137","author":"A Larocca","year":"2021","unstructured":"Larocca, A. et al. Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood 137, 3027\u20133036 (2021).","journal-title":"Blood"},{"key":"1186_CR30","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","volume":"131","author":"T Facon","year":"2018","unstructured":"Facon, T. et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood 131, 301\u2013310 (2018).","journal-title":"Blood"},{"key":"1186_CR31","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/S1470-2045(25)00280-3","volume":"26","author":"S Manier","year":"2025","unstructured":"Manier, S. et al. Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial. Lancet Oncol. 26, 1323\u20131333 (2025).","journal-title":"Lancet Oncol."},{"key":"1186_CR32","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41375-024-02505-2","volume":"39","author":"T Facon","year":"2025","unstructured":"Facon, T. et al. Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia 39, 942\u2013950 (2025).","journal-title":"Leukemia"},{"key":"1186_CR33","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson, P. G. et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N. Engl. J. Med. 387, 132\u2013147 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1186_CR34","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal, M. et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N. Engl. J. Med. 376, 1311\u20131320 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1186_CR35","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1056\/NEJMe2604761","volume":"395","author":"H Mian","year":"2026","unstructured":"Mian, H. & Costa, L. J. Time to stop? Rethinking the duration of maintenance treatment in MM. N. Engl. J. Med. 395, 302\u2013303 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1186_CR36","doi-asserted-by":"publisher","first-page":"5814","DOI":"10.1182\/blood-2025-5814","volume":"146","author":"B Razzo","year":"2025","unstructured":"Razzo, B. et al. Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed\/refractory multiple myeloma [abstract]. Blood 146, 5814\u20135815 (2025).","journal-title":"Blood"},{"key":"1186_CR37","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","volume":"10","author":"LJ Costa","year":"2023","unstructured":"Costa, L. J. et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 10, e890\u2013e901 (2023).","journal-title":"Lancet Haematol."},{"key":"1186_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01156-x","volume":"14","author":"BA Derman","year":"2024","unstructured":"Derman, B. A. et al. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 14, 170 (2024).","journal-title":"Blood Cancer J."},{"key":"1186_CR39","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1182\/blood.2022019531","volume":"142","author":"L Rosi\u00f1ol","year":"2023","unstructured":"Rosi\u00f1ol, L. et al. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. Blood 142, 1518\u20131528 (2023).","journal-title":"Blood"},{"key":"1186_CR40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/blood-2020-142913","volume":"136","author":"A Krishnan","year":"2020","unstructured":"Krishnan, A., Hoering, A., Hari, P., Sexton, R. & Orlowski, R. Z. Phase III study of daratumumab\/rhuph20 (nsc- 810307) + lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapyin patients with Multiple Myeloma (mm) using minimal residual disease todirect therapy duration (DRAMMATIC study): SWOG s1803 [abstract]. Blood 136, 21\u201322 (2020).","journal-title":"Blood"},{"key":"1186_CR41","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/JCO.18.00685","volume":"37","author":"EA Stadtmauer","year":"2019","unstructured":"Stadtmauer, E. A. et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial. J. Clin. Oncol. 37, 589\u2013597 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1186_CR42","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1056\/NEJMoa2505133","volume":"393","author":"A Perrot","year":"2025","unstructured":"Perrot, A. et al. Measurable residual disease-guided therapy in newly diagnosed myeloma. N. Engl. J. Med. 393, 425\u2013437 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1186_CR43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200210","author":"B Dhakal","year":"2024","unstructured":"Dhakal, B. et al. MRD-guided sequential therapy for deep response in newly diagnosed multiple myeloma (NDMM) \u2014 Master-2 trial. Blood https:\/\/doi.org\/10.1182\/blood-2024-200210 (2024).","journal-title":"Blood"},{"key":"1186_CR44","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1186_CR45","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388, 1002\u20131014 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1186_CR46","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","volume":"43","author":"S Jagannath","year":"2025","unstructured":"Jagannath, S. et al. Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J. Clin. Oncol. 43, 2766\u20132771 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1186_CR47","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335\u2013347 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1186_CR48","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1182\/blood-2021-146210","volume":"138","author":"D Dytfeld","year":"2021","unstructured":"Dytfeld, D. et al. Bortezomib, lenalidomide and dexamethasone (VRd) followed by ciltacabtagene autoleucel versus Vrd followed by lenalidomide and dexamethasone (Rd) maintenance in patients with newly diagnosed multiple myeloma not intended for transplant: a randomized, phase 3 study (CARTITUDE-5) [abstract]. Blood 138, 1835 (2021).","journal-title":"Blood"},{"key":"1186_CR49","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/01.HS9.0000936220.68605.8b","volume":"7","author":"A Broijl","year":"2023","unstructured":"Broijl, A. et al. Emagine\/Cartitude-6: a randomized phase 3 study of DVRd followed by ciltacabtagene autoleucel versus DVRd followed by autologous stem cell transplant in transplant-eligible patients with newly diagnosed multiple myeloma [abstract P23]. HemaSphere 7, 22\u201323 (2023).","journal-title":"HemaSphere"},{"key":"1186_CR50","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","volume":"6","author":"RE Clark","year":"2019","unstructured":"Clark, R. E. et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 6, e375\u2013e383 (2019).","journal-title":"Lancet Haematol."},{"key":"1186_CR51","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon, F. X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11, 1029\u20131035 (2010).","journal-title":"Lancet Oncol."},{"key":"1186_CR52","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross, D. M. et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122, 515\u2013522 (2013).","journal-title":"Blood"},{"key":"1186_CR53","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele, S. et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 19, 747\u2013757 (2018).","journal-title":"Lancet Oncol."},{"key":"1186_CR54","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa2310063","volume":"390","author":"T Munir","year":"2024","unstructured":"Munir, T. et al. Chronic lymphocytic leukemia therapy guided by measurable residual disease. N. Engl. J. Med. 390, 326\u2013337 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1186_CR55","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1182\/blood.2021014488","volume":"139","author":"CS Tam","year":"2022","unstructured":"Tam, C. S. et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood 139, 3278\u20133289 (2022).","journal-title":"Blood"},{"key":"1186_CR56","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"1186_CR57","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar, S. K. et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 21, 1317\u20131330 (2020).","journal-title":"Lancet Oncol."},{"key":"1186_CR58","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa2600157","volume":"395","author":"S Kumar","year":"2026","unstructured":"Kumar, S. et al. Continuous or fixed-duration maintenance therapy in multiple myeloma. N. Engl. J. Med. 395, 221\u2013232 (2026).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01186-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01186-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01186-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:02:05Z","timestamp":1789732925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01186-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1186"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01186-3","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"6 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.M. is an advisory board member for AbbVie, BMS, FORUS, GSK, Johnson & Johnson and Pfizer; and has received research funding from Pfizer. L.J.C. is an advisory board member for AbbVie, BMS, Caribou, Genentech, Johnson & Johnson, Pfizer and Sanofi; has received honoraria from AbbVie, Adaptive biotechnology, Amgen, BeOne, BMS, Caribou, Johnson & Johnson, Pfizer and Sanofi; and works in an institution that has received research support from AbbVie, BMS, Caribou, Genentech, Johnson & Johnson and Pfizer. M.M. has received honoraria and\/or research funding, and\/or is a consultant and\/or member of the speakers bureau for Adaptive, Amgen, Astellas Pharma, BMS, GSK, Janssen, Jazz, Menarini, Novartis, Pfizer, Sanofi, Stemline and Takeda; and holds equity in MaaT Pharma (publicly traded). A.G. works in an institution that has received research funding from CRISPR Therapeutics, Johnson & Johnson, Novartis and Tmunity; has received consulting fees from AbbVie, AstraZeneca, BMS, Johnson & Johnson, Novartis, Pfizer, Regeneron and Smart Immune; and is an IDMC\/DSMB member at AstraZeneca and Johnson & Johnson. S.V.R. is Chair of the International Myeloma Foundation Board of Directors; has received honoraria for CME Lectures for Medscape; declares intellectual property and royalties as an author and section editor for UpToDate (covering topics on plasma cell disorders); and served as principal investigator on multiple trials.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}